M1 Kliniken AG: Completion of the Sale of 100% Subsidiary HAEMATO Pharm GmbH to PHOENIX group

Berlin, February 02, 2026 – M1 Kliniken AG (ISIN: DE000A0STSQ8) announces that the sale of HAEMATO Pharm GmbH by its majority holding, HAEMATO AG (85%), to the PHOENIX group was successfully completed effective as of the end of January 31, 2026.

Following the fulfillment of all closing conditions, including the necessary antitrust approvals, the transaction has now been legally consummated. Consequently, HAEMATO Pharm GmbH will be deconsolidated from the scope of consolidation of both HAEMATO AG and M1 Kliniken AG.

With the successful closing of this transaction, M1 Kliniken AG continues to consistently pursue its strategic focus and strengthens its positioning as a leading global, vertically integrated pure-play provider of medical aesthetics.

About M1 Kliniken AG

M1 Kliniken AG is the leading fully integrated provider of medical aesthetic services in Europe and Australia. With a clear strategic focus, high standardization, and consistent scalability, the Group currently operates 58 clinics in ten countries under the M1 Med Beauty brand. All treatments are performed exclusively by qualified physicians and adhere to uniform, high medical standards, while being offered at market-leading prices. Since late 2018, M1 has systematically driven its international expansion, which forms the basis for scalable future growth and the further development of its global market position. With the M1 Schlossklinik in Berlin, the Group operates one of Europe’s largest and most modern clinics for plastic and aesthetic surgery, featuring four operating theaters and 35 beds.

Contact:
M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
T: +49 (0)30 347 47 44 14
M: ir@m1-kliniken.de

• Continued organic growth despite challenging comparative basis
• APAC region strongest growth driver
• Diversification contributes to stability and scalability
• Human clinical trials successfully completed, scientific visibility will increase

aap Implantate AG (“aap”) reports preliminary sales growth of 2% year-on-year for the financial year, thus confirming stable business performance with positive momentum in the fourth quarter. The main growth drivers were once again the Asian markets.

The sales decline of around 3% in the first half of 2025 – due to one-off major orders in the first half of 2024 – was fully compensated for in the further course of the year. In the second half of the year, aap achieved an increase in sales of 8% compared to the same period of the previous year. Most of the sales regions contributed to this development with improved performance in the second half of the year.

In Germany, sales increased by 5% despite persistently challenging market conditions, underlining the company’s solid market position in its home market. In the United States, the shortfall of –9% in local currency recorded in the first half of the year was gradually made up, resulting in a slight increase of 1% for the year.

The APAC region developed particularly strongly, with aap achieving significant revenue growth of 98% for the full year with existing and new customers, consolidating Asia’s role as an increasingly important growth driver for the company.

Sales FY/2025

In addition, the company made decisive progress in product development in the past fiscal year: The clinical human study on the innovative, antibacterial treated implants was successfully completed with excellent results. The complete study report is currently at the participating study centers for final approval.

The results are planned to be published in an internationally renowned journal later this year. This would further underpin the scientific relevance of technology and significantly increase its visibility in the global professional environment.

At the same time, the company is working with high priority on the approval of the new implants – both for the European market under the Medical Device Regulation (MDR) and for the US market under the regulations of the Food and Drug Administration (FDA). With the completion of these procedures, the company is creating the future basis for the global market launch of its exclusive “Silver Trauma Line” and the basis for licenses in other implant areas such as hip implants and others.

This step represents an important milestone and paves the way for the strategic development of the company into a new, international growth scenario.

The Company will provide information on the outlook for the 2026 financial year and the management agenda in a separate announcement.

The sales figures contained in this press release are preliminary figures as of December 31, 2025, and are subject to change until the final publication. aap plans to announce the final, audited results for the 2025 financial year at the end of April 2026 as part of the 2025 consolidated annual financial report.

——————————————————————————————————————————————-

aap Implantate AG (ISIN DE0005066609) – General Standard/Regulated Market – All German Stock Exchanges –

About aap Implantate AG

aap Implantate AG is a global medical technology company headquartered in Berlin, Germany. The company develops manufactures and markets products for traumatology. In addition to the innovative anatomical plate system LOQTEQ®, the IP-protected portfolio includes a wide range of perforated screws. In addition, aap Implantate AG has an innovative pipeline with promising development projects, such as antibacterial silver coating technology. This technology addresses critical and not yet adequately solved problems of Surgical Site Infections (SSI) in traumatology and applicable in other MedTech areas.  In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups and affiliated clinics, while on an international level, it primarily uses a broad network of distributors in around 41 countries. In the USA, the company and its subsidiary aap Implants Inc. rely on a distribution agent and selective direct sales strategy. The shares of aap Implantate AG are listed in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit our website at www.aap.de.

There may be technical rounding differences in the figures presented in this press release, which do not affect the overall statement.

Forward-Looking Statements

This release may contain forward-looking statements based on the current expectations, assumptions and forecasts of the Management Board and information currently available to it. The forward-looking statements are not to be understood as guarantees of future developments and results referred to therein. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial condition, development or performance of the Company to differ materially from the estimates given herein. These factors also include those described by aap in published reports. Forward-looking statements therefore speak only as of the date on which they are made. We undertake no obligation to update the forward-looking statements made in this release or to conform them to future events or developments.

If you have any questions, please contact: aap Implantate AG; Rubino Di Girolamo; Chairman of the Board of Directors/CEO; Lorenzweg 5; 12099 Berlin
Tel.: +49 (0)30 75019 – 141; Fax: +49 (0)30 75019 – 170; E-Mail: r.digirolamo@aap.de

Affluent Medical officially becomes CARVOLIX

Completion of the acquisitions of CARANX MEDICAL and ARTEDRONE

10m€ first tranche of financing completed

Aix-en-Provence, February 2, 2026 – 7:30 a.m. CET – Carvolix (formerly Affluent Medical) (ISIN: FR0013333077 – Ticker: AFME – “Carvolix” or the “Company”), a French commercial and clinical-stage medical technology company specializing in the international development and industrialization of breakthrough AI-driven mini-robots and biomimetic implants, to revolutionize interventional cardiology and the treatment of brain stroke is today announcing the completion of the acquisitions of Caranx Medical and Artedrone (the “Acquisitions”), for a closing price paid in Carvolix shares, to form a new, integrated MedTech company named Carvolix, as well as the definitive terms of the capital increases and the issuance of new shares (the “Financing” and, together with the Acquisitions, the “Transaction”) pursuant to the use of the delegations granted by the general meeting held on January 30, 2026 (the “General Meeting”).

A 10M€ first tranche of Financing has been made available by funds managed by Truffle Capital and by Edwards Lifesciences at a subscription price of €2.34 per share (which represents a 18.8% premium versus the last closing share price).

This strategic consolidation is designed to create a company for the 21^st century interventional cardiologist – leveraging world leading technology in AI driven autonomous mini-robots with a mission to democratize complex, life-saving procedures. The combined platforms position Carvolix to accelerate radical innovation, expand its addressable market, and drive long term value creation.

“We’re applying our proven business builder model — uniting the capabilities of Truffle-founded companies to de-risk development, accelerate innovation, generate synergies and unlock value for shareholders” said Philippe Pouletty, M.D., CEO of Truffle Capital, founder of several successful biotech and medtech companies (including Abivax, Vexim, Symetis and Affluent Medical).  He added: “We expect to make the cardiology catheterization lab as autonomous and efficient as an aircraft cockpit so that our radical innovations could potentially benefit to millions of patients worldwide.”

Carvolix will focus on revolutionizing cardiac valve replacement and brain stroke treatment, addressing major unmet medical needs in large markets with a total addressable value of €23 billion. Currently, only 17% of the 1.7 million patients annually eligible for Transcatheter Aortic Valve Implantation (TAVI) undergo the procedure, and only 5% of ischemic stroke patients (second cause of death, third cause of disability) receive mechanical thrombectomy. Similarly, just 4% of the four million patients with severe mitral valve regurgitation undergo surgery.

“We are bringing together three extremely innovative and synergistic MedTech companies into one – with the goal of augmenting the cardiac catheterization lab to treat far more patients suffering from valve dysfunction and brain stroke” said Sebastien Ladet, CEO of Carvolix. “In addition, we will boost synergies in R&D and commercialization between the three companies to enable the development and delivery of additional products, such as a robotically delivered mitral valve.”

The combination of these companies unites deep expertise and R&D synergies across micro-robotics, AI, image guidance and biomimetic  valve technologies — accelerating innovation and establishing a robust, sustained product development cadence.

The first product launch is occuring in early 2026, with the TAVIPILOT software ‘already cleared by the FDA, being introduced in the US.  The Company plans to keep direct commercialization rights in Europe and seek partners in the US, Middle East, and Asia.

“We are building a fantastic management team and board of directors to carry out our mission: a commercial stage MedTech leader dedicated to helping interventional cardiologists treat more patients around the world” said Liane Teplitsky, Executive Chair of the Board of Directors of Carvolix.

Completion of the Acquisitions

On December 19, 2025, the Company announced the upcoming acquisition of Caranx Medical and Artedrone, becoming Carvolix, pioneering cardiovascular therapies with AI driven autonomous mini-robots and innovative implants. On January 30, 2026, the Acquisitions have been formally completed and the consolidation of Caranx Medical and Artedrone with the pre-existing Affluent Medical entities into Carvolix is now effective.

The terms and conditions of the Acquisitions are further detailed in the Company press release dated December 19, 2025. In particular, Carvolix made closing payments of respectively €16.6M and €11.4M, entirely in Carvolix shares, for the acquisition of Caranx Medical and Artedrone. Carvolix also acquired from Truffle BioMedTech CrossOver FPCI a current account against Artedrone for an amount of €1M plus accrued interests (at a rate of 8% per annum) (the “Current Account”).

Truffle funds, acting as sellers in the context of the Acquisitions, entirely rolled-over the closing purchase price and the purchase price of the Current Account at a subscription price of €2.34 per ordinary share (i.e., the same price as for the Financing), resulting in the issuance of a total of 12,384,470 new ordinary shares.

These 12,384,470 new ordinary shares were issued by the Board of Directors on January 30, 2026 pursuant to the delegations granted by the general meeting of the Company held on January 30, 2026, for a total subscription price of €28,979,659.80 offset with the closing purchase price and the purchase price of the Current Account.

Initial Tranches of Financing

On December 19, 2025, the Company further announced the launch of a concomitant Financing of up to €30M led by Truffle Capital and Edwards Lifesciences who undertook to make available to the Company a first tranche of €10M (the “First Tranche”).  The Company will secure up to €300,000 from several business angels (the “Additional Tranche”, and together with the First Tranche, the “Initial Tranches”).

Following the adoption by shareholders of the appropriate resolutions at the General Meeting, the Board of Directors decided on January 30, 2026 to use the delegations granted by the General Meeting to proceed with the implementation of the Initial Tranches, consisting of 4,401,708 new ordinary shares at a subscription price of €2.34 per Financing Share (which represents a 18.8% premium versus the last closing share price).

The purpose of the Initial Tranches of the Financing is to extend the horizon of the Company’s cash position from December 2025 to the end of May 2026.

The Initial Tranches of the Financing will allow the Company to pursue clinical and regulatory development for all its devices, and to position itself favorably as it embarks on the next steps of value creation. These steps include, but are not limited to, launching the commercialization in the US of TAVIPILOT Software, negotiating a strategic agreement with an industrial player to speed up the clinical trials and marketing of Artus, progress towards first in human for the robotic platform for stroke treatment and continue the development and clinical activities of Epygon.

The allocation of the proceeds of the Initial Tranches between the different programs should be approximately as follows: 28% to TAVIpilot, 27% to Artus, 23% to structural heart devices (Kalios and Epygon), 22% to ARTE-DRONE.

The financing required to pursue the combined Carvolix activities over the next 12 months, according to current development plans, is estimated at around €26M, of which €10.3M is secured through the Initial Tranches of the Financing.

The Company expects to secure the remainder (i.e., an additional amount of €15.7M) from several international investors, with whom discussions are currently ongoing. The Company also expects to be able to further extend its cash runway through, among other things, the proceeds that would be generated from a potential partnership deal with regards to Artus, an artificial urinary sphincter currently in Carvolix’s product portfolio.

Conversion of the June 2025 convertible bonds

On June 20, 2025, the Company issued €5.4M in convertible bonds to some of its main historical shareholders (the “Convertible Bonds”). In accordance with their terms, the Convertible Bonds are immediately and automatically payable in connection with the implementation of the Financing.

Each bondholder has irrevocably undertaken to subscribe, by way of debt offset, to a capital increase concomitant to the First Tranche of the Financing, such that no cash reimbursement will be made in connection with the redemption of the Convertible Bonds. The ordinary shares issued in connection with the redemption of the Convertible Bonds are subscribed by the bondholders at a price of €1.872 per ordinary share (corresponding to a 20% discount).

Following the adoption by shareholders of the appropriate resolutions at the General Meeting, the Board of Directors decided on January 30, 2026 to use the delegations granted by the General Meeting to proceed with the redemption of the Convertible Bonds and the issuance of 3,107,305 ordinary shares (including 2,605,384 ordinary shares to be issued to Truffle Medeor FPCI) at a subscription price of €1.872 per ordinary share (which represents a 5% discount versus the last closing share price).

Impact of the Transaction on the share capital

Taking into account the share issues resulting from (i) the Roll-Over, (ii) the Initial Tranches of the Financing, and (iii) the redemption of the Convertible Bonds, the shareholding structure of the Company will be as follows:

The 19,893,483 shares issued will result in a dilution of 33.57% (on a non-diluted basis). Following such issuance, the Company’s share capital will amount to €5,924,367.50 divided into 59,243,675 shares with a nominal value of €0.10. A shareholder holding 1.00% of the Company’s share capital before the Transaction would therefore hold 0.66% of the capital after the completion of the Transaction.

As part of the Transaction, it is reminded that up to an additional 14,283,985 shares could be issued in connection with the payment of earn-outs for the acquisition of Caranx Medical and Artedrone as well as with the subsequent tranches of the Financing (assuming up to 20M€ in additional financing subscribed at a price of €2.34 per share), representing an additional dilution of 14% (on a non-diluted basis).

In accordance with applicable provisions of the French Commercial Code, each subscriber of ordinary shares has abstained from voting on the resolution related to the removal of shareholders’ preferential rights for its benefit at the General Meeting and, as the case may be, the representatives of the subscribers at the Board of Directors have abstained from participating to the relevant decisions of the Board of Directors.

Impact of the Transaction on the shareholders’ equity

The share of equity, based on the Company’s consolidated financial statements at June 30, 2025, would be as follows:

Governance

As previously announced, the Board has decided to appoint Mrs. Liane Teplitsky as Executive Chair of the Board of Directors in replacement of Mr. Michel Therin, who will continue to contribute to the Board as director, effective as from the date of closing of the Transaction.

Advisors

Dechert LLP acted as legal advisor to the Company in connection with the Transaction.

Settlement and Delivery – Documentation

The ordinary shares issued in connection with (i) the Roll-Over, (ii) the Initial Tranches of the Financing, and (iii) the redemption of the Convertible Bonds, are expected to be admitted to trading on Euronext on February 4, 2026.

Such ordinary shares will be subject to an application for admission to trading on Euronext on the same trading line as the existing ordinary shares of the Company currently listed on Euronext, under the same ISIN code FR0013333077.

The Transaction is not subject to a prospectus requiring approval by the Financial Markets Authority (the “AMF”). However, in accordance with Article 1.5.b bis of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017, as amended (the “Prospectus Regulation”), the Company will file with the AMF a document containing the information required in Annex IX of the Prospectus Regulation (the “Information Document”), with a view to the admission to trading on the regulated market of Euronext in Paris (“Euronext Paris”) of the Shares to be issued in connection with the Transaction. The Information Document is not subject to a review by the AMF.

Risk factors

Members of the public should take note of the risk factors relating to Carvolix and its business, as presented in Chapter 3 of the 2024 Universal Registration Document filed with the AMF on April 30, 2025 under number D.25-0356, which is available free of charge on Carvolix’s website (www.affluentmedical.com). The occurrence of all or some of these risks would be likely to have an adverse effect on the business activity, financial position, results, development, or outlook of Carvolix. Such events could have a material adverse effect on Carvolix’s share price. Members of the public should particularly take note of the following risks:

• Raising additional capital, including as a result of this Transaction or of further offerings to finance the development or the commercialization of Carvolix’s products, may cause dilution to the Company’s shareholders, restrict its operations or require it to relinquish rights to its products;
• Future sales of ordinary shares by existing shareholders or investors participating in the Transaction could depress the market price of the Company’s shares;
• The market price of the Company’s shares can be subject to significant fluctuations and may decrease below the issuance price retained in the context of the Transaction;
• Volatility and liquidity of the shares of the Company can be subject to significant fluctuations;
• The Company’s management will have broad discretion over the use of the proceeds from the Financing and may apply these proceeds in ways that may not result in an increase of the share price.

In particular, Carvolix has updated risk factor 3.4.1 “Liquidity risk” of the 2024 Universal Registration Document in order to take into account the Financing, as well as risk factor 3.4.3 “Dilution risk” of the 2024 Universal Registration Document (for more information about the dilution, please see the above capitalization table) to reflect that the exercise of all the dilutive instruments held by officers, directors and employees, the warrants issued to Kreos and the earn-outs granted in the context of the Acquisitions, would result in a dilution of 31% to existing shareholders on the basis of the Company’s current share capital.

This press release does not constitute a prospectus as referred to in Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017, as amended, or an offer to the public.

About Carvolix

Carvolix is a French medical technologies company, commercial and clinical stage, founded by Truffle Capital, that aims to become a global leader in the treatment of structural heart diseases and brain strokes, world’s leading causes of mortality and disability. Carvolix develops novel AI and imaging driven mini-robots that make complex procedures doble by interventional cardiologists, as well as biomimetics heart valves.

About Truffle Capital

Founded in 2001, Truffle Capital is an independent European Venture Capital firm specializing in disruptive technologies in the Life Sciences (Medtech and Biotech) and IT sectors (Fintech and Insurtech). Truffle Capital’s mission is to support the creation and development of innovative companies capable of becoming the leaders of tomorrow, and it has notably founded Abivax.

Managed by Philippe Pouletty, M.D. and Bernard-Louis Roques, Co-founders and co-CEOs, Truffle Capital manages €500 million in assets. It has raised more than €1.2 billion since its creation and has supported more than 124 companies in the digital technology and life sciences sectors. Discover more at www.truffle.com and follow us on LinkedIn.

Contacts :

Disclaimer

This press release contains forward-looking statements about Carvolix and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Carvolix’s financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Carvolix believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 3 of the 2024 Universal Registration Document filed with the AMF on April 30, 2025 under number D.25-0356, which is available on the Company’s website (www.affluentmedical.com), as well as the risks associated with changes in economic conditions, financial markets and the markets in which Carvolix operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Carvolix or that Carvolix does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Carvolix to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Carvolix in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.

This press release does not constitute a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the “Prospectus Regulation“). With respect to the member states of the European Economic Area (each, a “Relevant Member State“), no offer of the securities mentioned herein is made or will be made to the public in that Relevant Member State, except (i) to any legal person who is a qualified investor as defined in the Prospectus Regulation, (ii) to fewer than 150 natural or legal persons per Relevant Member State, or (iii) in other circumstances falling within Article 1(4) of the Prospectus Regulation; provided that none of these offers shall require the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Regulation. For the purposes of the foregoing, the expression “offer to the public” in any Relevant Member State has the meaning given to it in Article 2(d) of the Prospectus Regulation.

Solely for the purposes of each manufacturer’s product approval process, the target market assessment in respect of the securities offered in the Financing has led to the conclusion that, in relation to the type of clients criteria, (i) the target market for the securities is eligible counterparties and professional clients, each as defined in Directive 2014/65/EU, as amended (“MiFID II“); and (ii) all channels for distribution of the securities offered in the Financing to eligible counterparties and professional clients are appropriate. Any person subsequently offering, selling or recommending the shares (a “distributor“) should take into consideration the manufacturers’ client type assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the shares offered in the Financing (by either adopting or refining the manufacturers’ target market assessment) and determining appropriate distribution channels.

This press release has been prepared in French, German, Arabic and English. In the event of any discrepancy between the four versions of the press release, the French version shall prevail.

PRESS RELEASE

Heidelberg Pharma Received Development Milestone Payment from Partner Takeda

Ladenburg, Germany, 29 January 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it has received a milestone payment under the terms of its license agreement with partner Takeda based on the achievement of a clinical development milestone for Takeda’s investigational medicine that utilizes Amanitin-based Antibody Drug Conjugate (ATAC) technology licensed from Heidelberg Pharma. With the dosing of the first patient in a Phase I/II clinical trial in patients with solid tumors, a milestone payment to Heidelberg Pharma became due. Financial details were not disclosed.

Dr. Dongzhou Jeffery Liu, Chief Executive Officer of Heidelberg Pharma AG, commented: “We are very delighted that our partner Takeda is progressing the development of their investigational medicine that utilizes ATAC technology, and that we have received the according milestone payment. We congratulate the Takeda team and wish them every success in clinical development. With this, three candidates that leverage ATAC technology are now in clinical development, two that are proprietary to Heidelberg Pharma including HDP-101 (INN: pamlectabart tismanitin) and HDP-102, and one under the responsibility of our partner. For us, this is a further validation of the potential of our unique Amanitin-based ADC technology.”

Takeda exclusively licensed the worldwide development and commercialization rights from Heidelberg Pharma for the use of the ATAC technology with an antibody directed to a defined target and the resulting product candidate. Under the terms of the agreement, Takeda is responsible for the development, as well as commercialization, of the resulting product candidate.

About Heidelberg Pharma

Heidelberg Pharma is a biopharmaceutical company working on a new treatment approach in oncology and developing novel drugs based on its ADC technologies for the targeted and highly effective treatment of cancer. ADCs are antibody-drug conjugates that combine the specificity of antibodies with the efficacy of toxins to fight cancer. Selected antibodies are loaded with cytotoxic compounds, that are transported into diseased cells. Inside the cells, the toxins then unleash their effect and kill the diseased cells.

Heidelberg Pharma is the first company to use the compound Amanitin from the green death cap mushroom in cancer therapy. The biological mechanism of action of the toxin represents a new therapeutic modality and is used as a compound in the Amanitin-based ADC technology, the so-called ATAC technology.

The lead candidate HDP-101 (INN: pamlectabart tismanitin) is a BCMA ATAC in clinical development for multiple myeloma. The candidate has been granted Orphan Drug Designation and Fast Track Designation from the FDA. A second ATAC candidate, HDP-102 is in clinical development stage in Non-Hodgkin Lymphoma. HDP-103 against metastatic castration-resistant prostate cancer and HDP-104 targeting gastrointestinal tumors such as colorectal cancer have completed preclinical development. Heidelberg Pharma is open for partnering.

The company is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com

ATAC^® is a registered trademark of Heidelberg Pharma Research GmbH. 

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

Fiscal Year 2025 (preliminary):

• Sales: approx. € 312 million (PY: € 295.8 million)
• EBIT before special items: approx. € 78 million (PY: € 65.9 million)
• Net income: approx. € 48 million (PY: € 33.3 million)

Berlin, 29 January 2026. According to preliminary, unaudited figures for the 2025 financial year, Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of around € 312 million and adjusted EBIT of around € 78 million. Sales are up around 5% on the previous year, while adjusted EBIT is up by around 18%. Net profit (from continuing and discontinued operations), which is only reported here for comparison purposes, rose to around € 48 million (previous year: € 33.3 million).

The forecast for the 2026 financial year will be published on 26 March 2026 together with the complete, audited annual financial statements for the 2025 financial year.

About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com 

PRESS RELEASE

MHH to Present Scientific Findings on Cold Plasma Therapy for Pulmonary Application at Press Conference in February 2026

Rellingen, 27 January 2026 – On 12 February 2026, Hannover Medical School (MHH) – represented by Prof. Dr. Hortense Slevogt – plans to hold a press conference together with the team from the Helmholtz Centre for Infection Research (HZI) in Braunschweig.

The focus of the event will be the presentation and scientific classification of a groundbreaking cold plasma therapy for application in the lungs. For Viromed stakeholders, the findings are of high strategic relevance, as they address a medical field in which there is an urgent and, to date, insufficiently met clinical need worldwide: severe pulmonary infections – particularly in vulnerable patient groups and in intensive care settings.

The relevance of the topic is driven in particular by three key factors:

• High global disease burden: Pulmonary infections and associated complications affect millions of patients worldwide every year and represent one of the major challenges of modern acute and intensive care medicine.
• Growing therapeutic limitations: The increasing prevalence of antibiotic-resistant pathogens further exacerbates the situation and intensifies the pressure to develop new and effective therapeutic approaches.
• New physical treatment option: The planned publication of an innovative physical therapy principle for the lungs potentially represents a paradigm shift in infection treatment and opens up the prospect of scalable clinical application.

About Viromed Medical AG

Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential.

www.viromed-medical-ag.de

Contact Viromed

E-Mail: kontakt@viromed-medical.de
 

Press contact

E-mail: viromed@kirchhoff.de